Should older hepatitis b patients with normal ALT get antivirals? new study explores

NCT ID NCT07637214

Completed Knowledge-focused Sponsor: Tongji Hospital Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study followed 250 chronic hepatitis B patients over age 30 who had detectable virus but normal liver enzyme levels (ALT). All had never received antiviral treatment before. Researchers measured how many became virus-negative after 48 weeks of antiviral therapy, and how many normalized their ALT levels. The goal is to understand whether treating this group is beneficial.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: antiviral therapy (nucleoside analogues or interferon-α)
What this could lead to: If successful, this could help doctors decide whether to treat chronic hepatitis B patients who have normal liver enzyme levels, potentially preventing future liver damage.
What could go wrong: This is an observational study, not a controlled trial, so results may not prove cause and effect. The sample size is moderate, and findings may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Bronchiolitis Obliterans Syndrome hepatitis B virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC HEPATITIS B TREATMENT

Contacts and locations

Locations

Tongji Hospital,Wuhan,Hubei

Wuhan, Hubei, 430000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.